NL301279I2 - Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents
Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zoutInfo
- Publication number
- NL301279I2 NL301279I2 NL301279C NL301279C NL301279I2 NL 301279 I2 NL301279 I2 NL 301279I2 NL 301279 C NL301279 C NL 301279C NL 301279 C NL301279 C NL 301279C NL 301279 I2 NL301279 I2 NL 301279I2
- Authority
- NL
- Netherlands
- Prior art keywords
- adagrasib
- optionally
- pharmaceutically acceptable
- acceptable salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586775P | 2017-11-15 | 2017-11-15 | |
| PCT/US2018/061060 WO2019099524A1 (en) | 2017-11-15 | 2018-11-14 | Kras g12c inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL301279I2 true NL301279I2 (nl) | 2024-08-01 |
Family
ID=66431793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301279C NL301279I2 (nl) | 2017-11-15 | 2024-06-10 | Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US10689377B2 (nl) |
| EP (3) | EP3710439B1 (nl) |
| JP (2) | JP7322019B2 (nl) |
| KR (1) | KR102861303B1 (nl) |
| CN (2) | CN118459460A (nl) |
| AU (1) | AU2018369759B2 (nl) |
| BR (1) | BR112020009818A2 (nl) |
| CA (1) | CA3082579A1 (nl) |
| CL (1) | CL2020001271A1 (nl) |
| CO (1) | CO2020007244A2 (nl) |
| CY (2) | CY1125974T1 (nl) |
| DK (1) | DK3710439T3 (nl) |
| EA (1) | EA202091186A1 (nl) |
| ES (2) | ES2944547T3 (nl) |
| FI (2) | FI3710439T3 (nl) |
| FR (1) | FR24C1026I2 (nl) |
| HR (1) | HRP20230377T1 (nl) |
| HU (2) | HUE061599T2 (nl) |
| IL (1) | IL274601B2 (nl) |
| LT (2) | LT3710439T (nl) |
| MX (1) | MX2020005063A (nl) |
| MY (1) | MY200356A (nl) |
| NL (1) | NL301279I2 (nl) |
| PH (1) | PH12020550622A1 (nl) |
| PL (1) | PL3710439T3 (nl) |
| PT (1) | PT3710439T (nl) |
| RS (1) | RS64182B1 (nl) |
| SA (1) | SA520411982B1 (nl) |
| SG (1) | SG11202004427TA (nl) |
| SI (1) | SI3710439T1 (nl) |
| TW (1) | TWI809005B (nl) |
| UA (1) | UA125802C2 (nl) |
| WO (2) | WO2019099524A1 (nl) |
| ZA (1) | ZA202002105B (nl) |
Families Citing this family (202)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| MX2020005063A (es) * | 2017-11-15 | 2021-01-08 | Mirati Therapeutics Inc | Inhibidores de kras g12c. |
| MA52501A (fr) * | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| US20210230170A1 (en) * | 2018-08-31 | 2021-07-29 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| JP2022500388A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| EP4552631A3 (en) | 2018-09-10 | 2025-07-02 | Mirati Therapeutics, Inc. | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer |
| MX2021002805A (es) | 2018-09-10 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| FI3735299T3 (fi) | 2018-11-09 | 2024-12-04 | Hoffmann La Roche | Fuusioituja rengasyhdisteitä |
| WO2020118066A1 (en) * | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP4249000A3 (en) | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| MX2021010674A (es) | 2019-03-05 | 2021-09-28 | Astrazeneca Ab | Compuestos triciclicos condensados utiles como agentes anticancerigenos. |
| TW202110837A (zh) * | 2019-05-24 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| CN112047939B (zh) * | 2019-06-06 | 2023-05-02 | 江苏先声药业有限公司 | 一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物 |
| CN112300153B (zh) * | 2019-07-26 | 2023-06-13 | 博瑞生物医药（苏州）股份有限公司 | 一种杂环化合物、药物组合物和用途 |
| CA3149403A1 (en) * | 2019-08-02 | 2021-02-11 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Tetracyclic compound, preparation method and use thereof |
| TWI752580B (zh) * | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
| CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN112390797A (zh) * | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| WO2021043322A1 (zh) * | 2019-09-06 | 2021-03-11 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4034123A4 (en) * | 2019-09-24 | 2023-11-01 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| CN112552295A (zh) * | 2019-09-25 | 2021-03-26 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| US12478624B2 (en) | 2019-10-02 | 2025-11-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN114555586B (zh) * | 2019-10-10 | 2023-06-23 | 信达生物制药(苏州)有限公司 | Krasg12c蛋白抑制剂及其制备方法和用途 |
| CN112694475B (zh) * | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| ES3000619T3 (en) * | 2019-10-30 | 2025-03-03 | Genfleet Therapeutics Shanghai Inc | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| BR112022008535A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| WO2021088458A1 (en) * | 2019-11-04 | 2021-05-14 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitor |
| WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN112778301A (zh) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| CN112824410A (zh) * | 2019-11-21 | 2021-05-21 | 苏州泽璟生物制药股份有限公司 | 氮杂七元环类抑制剂及其制备方法和应用 |
| JP7670711B2 (ja) | 2019-11-27 | 2025-04-30 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | ジアリール大環状化合物を含む併用療法 |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| EP4015520B1 (en) * | 2019-12-02 | 2025-02-19 | 280 Bio, Inc. | Oxygen-containing heterocyclic compound, preparation method and application thereof |
| CN117820333A (zh) | 2019-12-11 | 2024-04-05 | 伊莱利利公司 | Kras g12c抑制剂 |
| CN113004269B (zh) * | 2019-12-19 | 2024-11-05 | 首药控股(北京)股份有限公司 | Kras-G12C抑制剂杂环化合物 |
| TWI871397B (zh) * | 2019-12-19 | 2025-02-01 | 大陸商北京加科思新藥研發有限公司 | Ｋｒａｓ突變蛋白抑制劑 |
| JP2023507571A (ja) | 2019-12-20 | 2023-02-24 | ミラティ セラピューティクス， インコーポレイテッド | Ｓｏｓ１阻害剤 |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| CN113045565A (zh) * | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| CN112094269B (zh) * | 2020-01-01 | 2021-12-07 | 上海凌达生物医药有限公司 | 一类饱和六元环并杂环类化合物、制备方法和用途 |
| CN113087700B (zh) * | 2020-01-08 | 2023-03-14 | 苏州亚盛药业有限公司 | 螺环四氢喹唑啉 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| JP2023515479A (ja) * | 2020-02-20 | 2023-04-13 | ベータ・ファーマ・インコーポレイテッド | Ｋｒａｓ阻害剤としてのピリドピリミジン誘導体 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| TW202140450A (zh) * | 2020-02-24 | 2021-11-01 | 大陸商泰勵生物科技（上海）有限公司 | 用於癌症治療的ｋｒａｓ抑制劑 |
| EP4105211A4 (en) * | 2020-03-12 | 2023-09-06 | D3 Bio(Wuxi) Co., Ltd. | Pyrimidoheterocyclic compounds and application thereof |
| CN115427414A (zh) * | 2020-04-28 | 2022-12-02 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
| WO2021219072A1 (zh) * | 2020-04-30 | 2021-11-04 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113666923A (zh) * | 2020-05-15 | 2021-11-19 | 苏州泽璟生物制药股份有限公司 | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 |
| AU2021285032A1 (en) | 2020-06-02 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| AU2021283585A1 (en) * | 2020-06-04 | 2022-11-17 | Antengene Discovery Limited | Inhibitors of KRAS G12C protein and uses thereof |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| EP4171570A1 (en) | 2020-06-24 | 2023-05-03 | Boehringer Ingelheim International GmbH | Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor |
| US12472179B2 (en) | 2020-06-25 | 2025-11-18 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| CN113912608B (zh) * | 2020-07-10 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 |
| CN113980014B (zh) * | 2020-07-27 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| KR20230053661A (ko) * | 2020-08-17 | 2023-04-21 | 베타 파머수티컬 컴퍼니 리미티드 | 비사이클 화합물과 비사이클 화합물을 포함하는 조성물 및 이들의 용도 |
| JP2023540270A (ja) | 2020-08-28 | 2023-09-22 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4206201A4 (en) | 2020-09-11 | 2024-09-11 | Medshine Discovery Inc. | CRYSTALLINE FORM OF AN AZETIDINE-SUBSTITUTED COMPOUND |
| MX2023002942A (es) * | 2020-09-11 | 2023-05-22 | Mirati Therapeutics Inc | Formas cristalinas de un inhibidor de kras g12c. |
| CN116601151A (zh) * | 2020-09-11 | 2023-08-15 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂的晶型 |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| WO2022081655A1 (en) * | 2020-10-14 | 2022-04-21 | Accutar Biotechnology, Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
| US20230383359A1 (en) * | 2020-10-23 | 2023-11-30 | Mirati Therapeutics, Inc. | Methods for treatment of lung cancers |
| US20240116900A1 (en) * | 2020-10-30 | 2024-04-11 | Novartis Ag | New crystalline forms of a kras g12c inhibitor compound |
| CN120887884A (zh) | 2020-11-06 | 2025-11-04 | 泰励生物科技（上海）有限公司 | 用于癌症治疗的KRas抑制剂 |
| US20230416266A1 (en) * | 2020-11-23 | 2023-12-28 | Merck Sharp & Dohme Corp. | 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT |
| CN114591319B (zh) * | 2020-12-04 | 2024-06-28 | 江苏先声药业有限公司 | 四氢吡啶并嘧啶类衍生物及其用途 |
| CN116829151A (zh) * | 2020-12-15 | 2023-09-29 | 米拉蒂治疗股份有限公司 | 氮杂喹唑啉泛KRas抑制剂 |
| AU2021401232A1 (en) * | 2020-12-15 | 2023-06-22 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| WO2022133038A1 (en) * | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN116529249A (zh) * | 2020-12-18 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 吡啶并嘧啶酮类化合物 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2021400059A1 (en) | 2020-12-18 | 2023-07-06 | Amphista Therapeutics Limited | Novel bifunctional molecules for targeted protein degradation |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022135346A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers |
| CN114716436A (zh) * | 2021-01-04 | 2022-07-08 | 广州百霆医药科技有限公司 | Kras g12c突变抑制剂及其用途 |
| WO2022148421A1 (en) * | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022165142A1 (en) * | 2021-01-29 | 2022-08-04 | Mirati Therapeutics, Inc. | Combination therapies |
| US20250066387A9 (en) * | 2021-02-01 | 2025-02-27 | D3 Bio (Wuxi) Co., Ltd. | Pyrimidopyran compound |
| WO2022171143A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物 |
| WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
| JP2024509625A (ja) | 2021-03-15 | 2024-03-04 | ノバルティス アーゲー | ベンゾイソオキサゾール誘導体及びその使用 |
| CN116801883A (zh) * | 2021-03-18 | 2023-09-22 | 四川科伦博泰生物医药股份有限公司 | 一类杂芳环化合物、其制备方法及用途 |
| US12077539B2 (en) | 2021-03-22 | 2024-09-03 | Incyte Corporation | Imidazole and triazole KRAS inhibitors |
| CN115124524A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
| CN116157400B (zh) * | 2021-03-30 | 2024-10-22 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| MX2023011856A (es) | 2021-04-08 | 2024-01-08 | Mirati Therapeutics Inc | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. |
| WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
| US20240238294A1 (en) | 2021-04-09 | 2024-07-18 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| CN117203208A (zh) * | 2021-04-23 | 2023-12-08 | 清华大学 | 靶向活化与失活态kras g12d的抑制剂 |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| CN118561952A (zh) | 2021-05-05 | 2024-08-30 | 锐新医药公司 | Ras抑制剂 |
| EP4340883A1 (en) * | 2021-05-19 | 2024-03-27 | Genentech, Inc. | Combination therapy |
| CN117813306A (zh) * | 2021-05-22 | 2024-04-02 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| JP2024521788A (ja) * | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| WO2022251576A1 (en) * | 2021-05-28 | 2022-12-01 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN117769554A (zh) * | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
| JP7668908B2 (ja) | 2021-06-09 | 2025-04-25 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| CN117529321A (zh) * | 2021-06-18 | 2024-02-06 | 上海德琪医药科技有限公司 | Erk抑制剂和kras抑制剂的组合及其用途 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| EP4367117A1 (en) | 2021-07-07 | 2024-05-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CN117751116A (zh) * | 2021-07-07 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为KRas G12D抑制剂的稠环化合物 |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| WO2023283933A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Biotech Co., Ltd. | Compounds useful as kras g12d inhibitors |
| AU2022320304A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN113527294A (zh) * | 2021-08-25 | 2021-10-22 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| AU2022336415A1 (en) | 2021-09-01 | 2024-01-04 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| KR20240073870A (ko) * | 2021-09-09 | 2024-05-27 | 미라티 테라퓨틱스, 인크. | Adagrasib의 합성을 위한 방법 및 중간체 |
| CN118043330A (zh) * | 2021-09-29 | 2024-05-14 | 海南先声再明医药股份有限公司 | Kras g12d抑制剂化合物及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN118176193A (zh) | 2021-10-22 | 2024-06-11 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| CA3236238A1 (en) | 2021-11-05 | 2023-05-11 | Frontier Medicines Corporation | Kras g12c inhibitors |
| WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| JP2024543912A (ja) | 2021-11-24 | 2024-11-26 | ジェネンテック， インコーポレイテッド | 二環式治療用化合物及びがんの処置における使用方法 |
| CA3240980A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023098425A1 (zh) * | 2021-12-02 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其制备和在药学上的应用 |
| EP4448526A1 (en) | 2021-12-17 | 2024-10-23 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023117681A1 (en) | 2021-12-22 | 2023-06-29 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds for the treatment of cancer |
| TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
| CN114409653A (zh) * | 2021-12-31 | 2022-04-29 | 苏州闻天医药科技有限公司 | 一种桥环并嘧啶并环类化合物及其用途 |
| TWI841200B (zh) * | 2022-01-21 | 2024-05-01 | 大陸商上海湃隆生物科技有限公司 | 雜環類化合物、藥物組成物及其應用 |
| JP2025506484A (ja) * | 2022-02-11 | 2025-03-11 | ウェイブ ライフ サイエンシズ リミテッド | キラル化合物の立体選択的技術 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| JP2025508133A (ja) | 2022-03-11 | 2025-03-21 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| EP4499233A1 (en) | 2022-03-25 | 2025-02-05 | Eli Lilly and Company | Kras inhibitors |
| MX2024010728A (es) | 2022-03-31 | 2024-09-10 | Eisai R&D Man Co Ltd | Composicion farmaceutica para tratar tumores. |
| EP4504203A1 (en) | 2022-04-04 | 2025-02-12 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| EP4511372A1 (en) * | 2022-04-18 | 2025-02-26 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
| CA3256645A1 (en) | 2022-05-06 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS |
| CN114907387B (zh) * | 2022-05-26 | 2023-11-10 | 中山大学 | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 |
| CN117164526A (zh) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用 |
| CN117164580A (zh) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | 一种kras g12c抑制剂的制备方法及其中间体 |
| CN119317629A (zh) * | 2022-06-10 | 2025-01-14 | 百时美施贵宝公司 | 作为kras抑制剂的四氢吡啶并3,4-d嘧啶衍生物 |
| CN119998298A (zh) | 2022-06-10 | 2025-05-13 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024039897A2 (en) | 2022-08-19 | 2024-02-22 | Mirati Therapeutics, Inc. | Adagrasib solid pharmaceutical compositions |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| AU2023385486A1 (en) | 2022-11-21 | 2025-06-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| CN116789609A (zh) * | 2023-03-03 | 2023-09-22 | 南京优氟医药科技有限公司 | 一种(r)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法 |
| CN116768804A (zh) * | 2023-03-15 | 2023-09-19 | 南京优氟医药科技有限公司 | 一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法 |
| KR20250164300A (ko) | 2023-03-30 | 2025-11-24 | 일라이 릴리 앤드 캄파니 | KRas 억제제 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024206766A1 (en) | 2023-03-31 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| WO2024229444A2 (en) * | 2023-05-04 | 2024-11-07 | Frontier Medicines Corporation | Mutant kras inhibitors and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024246114A1 (en) | 2023-05-31 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Survivin as a biomarker for predicting the responsiveness of cancer treatment |
| CN116675690A (zh) * | 2023-06-02 | 2023-09-01 | 北京康立生医药技术开发有限公司 | 一种肺癌治疗药物的制备方法 |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
| CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
| CN121263417A (zh) | 2023-06-30 | 2026-01-02 | 金橘生物科技公司 | 取代的稠合三环胺化合物及其作为ras抑制剂的用途 |
| WO2025019688A2 (en) * | 2023-07-20 | 2025-01-23 | Mirati Therapeutics, Inc. | Crystalline forms of salts of adagrasib |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250101043A1 (en) | 2023-09-27 | 2025-03-27 | Eli Lilly And Company | Kras inhibitors |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| US20250205238A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025242126A1 (zh) * | 2024-05-22 | 2025-11-27 | 上海正大天晴医药科技开发有限公司 | 一种药物组合及其应用 |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026003808A1 (en) | 2024-06-28 | 2026-01-02 | Assia Chemical Industries Ltd. | Solid state form of adagrasib and process for preparation |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0116662A (pt) | 2001-01-02 | 2003-09-23 | Hoffmann La Roche | Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| GEP20135925B (en) | 2007-03-14 | 2013-10-10 | Exelixis Patent Co Llc | Inhibitors of hedgehog pathway |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| US20090253693A1 (en) | 2008-04-07 | 2009-10-08 | Dmitry Koltun | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| EP2318377B1 (en) | 2008-07-31 | 2013-08-21 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| WO2011078369A1 (ja) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | 新規アリールウレア誘導体 |
| US20110269244A1 (en) | 2009-12-30 | 2011-11-03 | Petter Russell C | Ligand-directed covalent modification of protein |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| US9695133B2 (en) | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| MX364438B (es) | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JP6559123B2 (ja) * | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| CA2950581A1 (en) | 2014-05-30 | 2015-12-03 | The Trustees Of Columbia University In The City Of New York | Multivalent ras binding compounds |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
| KR20180005178A (ko) | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | 치환된 퀴나졸린 화합물 및 이의 사용방법 |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| US10421764B2 (en) | 2015-04-24 | 2019-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Mutant KRas inhibitors |
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| KR20180051626A (ko) | 2015-09-24 | 2018-05-16 | 아이오니스 파마수티컬즈, 인코포레이티드 | Kras 발현의 조절제 |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| US10670605B2 (en) | 2015-10-22 | 2020-06-02 | The Scripps Research Institute | Cysteine reactive probes and uses thereof |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| WO2017079864A1 (en) | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
| AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| WO2018102453A1 (en) | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CN110769823A (zh) | 2016-11-30 | 2020-02-07 | 班塔姆制药有限责任公司 | 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法 |
| MX392368B (es) | 2016-12-15 | 2025-03-24 | Univ California | Composiciones y metodos para el tratamiento del cancer |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| KR20230150408A (ko) | 2016-12-22 | 2023-10-30 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
| US10344026B2 (en) | 2017-01-18 | 2019-07-09 | Nantbio, Inc. | Compositions and methods of targeting mutant K-ras |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| CN110382483A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的n-杂环化合物及其使用方法 |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| US10647715B2 (en) * | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| MX2020005063A (es) * | 2017-11-15 | 2021-01-08 | Mirati Therapeutics Inc | Inhibidores de kras g12c. |
| US10597405B2 (en) | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
-
2018
- 2018-11-14 MX MX2020005063A patent/MX2020005063A/es unknown
- 2018-11-14 HU HUE18879484A patent/HUE061599T2/hu unknown
- 2018-11-14 EP EP18879484.6A patent/EP3710439B1/en active Active
- 2018-11-14 FI FIEP18879484.6T patent/FI3710439T3/fi active
- 2018-11-14 ES ES18879484T patent/ES2944547T3/es active Active
- 2018-11-14 HR HRP20230377TT patent/HRP20230377T1/hr unknown
- 2018-11-14 MY MYPI2020001151A patent/MY200356A/en unknown
- 2018-11-14 BR BR112020009818-3A patent/BR112020009818A2/pt unknown
- 2018-11-14 PT PT188794846T patent/PT3710439T/pt unknown
- 2018-11-14 EA EA202091186A patent/EA202091186A1/ru unknown
- 2018-11-14 RS RS20230345A patent/RS64182B1/sr unknown
- 2018-11-14 DK DK18879484.6T patent/DK3710439T3/da active
- 2018-11-14 US US16/191,190 patent/US10689377B2/en active Active
- 2018-11-14 KR KR1020207016494A patent/KR102861303B1/ko active Active
- 2018-11-14 PL PL18879484.6T patent/PL3710439T3/pl unknown
- 2018-11-14 UA UAA202003509A patent/UA125802C2/uk unknown
- 2018-11-14 SI SI201830912T patent/SI3710439T1/sl unknown
- 2018-11-14 CN CN202410549759.9A patent/CN118459460A/zh active Pending
- 2018-11-14 SG SG11202004427TA patent/SG11202004427TA/en unknown
- 2018-11-14 LT LTEPPCT/US2018/061060T patent/LT3710439T/lt unknown
- 2018-11-14 CA CA3082579A patent/CA3082579A1/en active Pending
- 2018-11-14 CN CN201880086849.1A patent/CN111989321B/zh active Active
- 2018-11-14 IL IL274601A patent/IL274601B2/en unknown
- 2018-11-14 JP JP2020526612A patent/JP7322019B2/ja active Active
- 2018-11-14 AU AU2018369759A patent/AU2018369759B2/en active Active
- 2018-11-14 WO PCT/US2018/061060 patent/WO2019099524A1/en not_active Ceased
- 2018-11-15 TW TW107140665A patent/TWI809005B/zh active
-
2019
- 2019-05-14 EP EP24206860.9A patent/EP4501932A3/en active Pending
- 2019-05-14 ES ES19886028T patent/ES3009544T3/es active Active
- 2019-05-14 EP EP19886028.0A patent/EP3880208B1/en active Active
- 2019-05-14 JP JP2021526287A patent/JP7346565B2/ja active Active
- 2019-05-14 WO PCT/US2019/032249 patent/WO2020101736A1/en not_active Ceased
-
2020
- 2020-05-04 ZA ZA2020/02105A patent/ZA202002105B/en unknown
- 2020-05-06 US US16/868,258 patent/US20200262837A1/en not_active Abandoned
- 2020-05-13 CL CL2020001271A patent/CL2020001271A1/es unknown
- 2020-05-13 PH PH12020550622A patent/PH12020550622A1/en unknown
- 2020-05-15 SA SA520411982A patent/SA520411982B1/ar unknown
- 2020-06-12 CO CONC2020/0007244A patent/CO2020007244A2/es unknown
-
2022
- 2022-10-21 US US18/048,834 patent/US20230373999A1/en not_active Abandoned
-
2023
- 2023-05-10 CY CY20231100226T patent/CY1125974T1/el unknown
- 2023-08-04 US US18/230,580 patent/US20240101553A1/en active Pending
-
2024
- 2024-06-10 NL NL301279C patent/NL301279I2/nl unknown
- 2024-06-10 FI FIC20240021C patent/FIC20240021I1/fi unknown
- 2024-06-11 HU HUS2400019C patent/HUS2400019I1/hu unknown
- 2024-06-11 LT LTPA2024517C patent/LTC3710439I2/lt unknown
- 2024-06-13 FR FR24C1026C patent/FR24C1026I2/fr active Active
- 2024-06-13 CY CY2024020C patent/CY2024020I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301279I2 (nl) | Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301342I2 (nl) | Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301329I2 (nl) | Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301224I2 (nl) | Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301341I2 (nl) | eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301245I2 (nl) | Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301161I2 (nl) | zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301155I2 (nl) | abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301286I2 (nl) | Danicopan, of een farmaceutisch aanvaardbaar zout ervan | |
| NL301260I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| NL301327I2 (nl) | Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan | |
| NL301149I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301344I2 (nl) | lnavolisib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301238I2 (nl) | Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301128I2 (nl) | Risdiplam of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301111I2 (nl) | Entrectinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301208I2 (nl) | capmatinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301212I2 (nl) | Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium | |
| NL301292I2 (nl) | Iptacopan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301253I2 (nl) | mavacamten of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301006I2 (nl) | Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| FIC20265004I1 (fi) | Sebetralstaatti tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti | |
| NO2025050I1 (no) | Acalabrutinib or a pharmaceutically acceptable salt thereof, in combination with venetoclax optionally with or without obinutuzumab | |
| NL301326I2 (nl) | imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2022009I1 (no) | Lumasiran, optionally in the form of a salt |